Onychomycosis is a common disease, and there are a number of factors that may affect the duration and dosage of treatment including the type of onychomycosis, the area and thickness of nail involvement, the age of the patient, and the location of the digit that is affected.
Hand Dermatitis can have a significant impact on quality of life. It may interfere with activities both at work and in the home and can be associated with social and psychological distress. This article provides helpful practical guidance for the general practitioner in the management of patients with Hand Dermatitis.
Update and discussion on onychomycosis (nail fungus) and Efinaconazole 10%. Recent clinical trial results, and discussion about patient safety profile, special cases like diabetic patients, and cure rates.
Toenail Onychomycosis – A Canadian Approach with a New Transungal Treatment – a Podiatrist Perspective
A recently published clinical pathway for Toe Onychomycosis is used as the basis for the management strategy presented here, and follows a pathway reflective of the therapeutic options available in Canada.
Device-based therapies are promising alternatives for the treatment of onychomycosis because they can mitigate some of the negative factors associated with treatment failure. This article reviews the case for laser and light based therapies, for the treatment of nail fungus.
Nail fungus, left untreated, the infection can spread to other nails and potentially cause further complications. This article reviews efinaconazole 10% as a topical monotherapy. Clinical trial data, mechanism of action, and future treatments are discussed.
Onychomycosis is a stubborn fungal infection of the nails that can be difficult to manage. Clinical trial data of Tavaborole is considered, as it allows for effective nail penetration compared to ciclopirox and amorolfine lacquers.
There has been much discussion about the optimal treatment for onychomycosis. We propose a simple algorithmic approach to aid in the selection of therapy for dermatophyte toenail onychomycosis and present a balance between efficacy and risk of therapy.
Onychomycosis is a fungal infection of the nail caused by dermatophytes, yeasts, or non-dermatophyte molds. Here we discuss using topical Efinaconazole in the management of toenail onychomycosis.
Onychomycosis has a significant impact on the patient. With three new, orally effective, antifungal agents, we have for the first time effective treatment that can provide benefit for a high percentage of patients. This review examines some of the areas of uncertainty and controversy.
Efinaconazole in the Treatment of Onychomycosis: Managing Patient Expectations and Promoting Compliance
Onychomycosis, also known as tinea unguium, is a progressive fungal infection of the nails resulting in discoloration, nail plate thickening, and onycholysis. Efinaconazole 10% solution is an effective and convenient topical antifungal treatment for onychomycosis, with toenail mycological cure rates between 53.4% and 55.2% and complete cure rates between 15.2% and 17.8%.
Onychomycosis is one of the most common nail disorders. Despite recent therapeutic advances with the introduction of effective systemic agents and transungual drug delivery systems, the incidence of onychomycosis is increasing.